Neuberger Berman Group LLC Buys 269,015 Shares of DaVita Inc. $DVA

Neuberger Berman Group LLC boosted its stake in DaVita Inc. (NYSE:DVA) by 138.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 463,250 shares of the company’s stock after acquiring an additional 269,015 shares during the quarter. Neuberger Berman Group LLC’s holdings in DaVita were worth $61,502,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in DVA. NewEdge Advisors LLC boosted its position in shares of DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after buying an additional 88 shares during the period. Goldman Sachs Group Inc. boosted its position in DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after acquiring an additional 28,739 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of DaVita by 1.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock worth $954,000 after acquiring an additional 94 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in shares of DaVita by 48.1% in the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Versor Investments LP lifted its position in shares of DaVita by 9.2% in the second quarter. Versor Investments LP now owns 1,740 shares of the company’s stock worth $248,000 after purchasing an additional 146 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on DVA shares. Barclays raised their target price on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. UBS Group increased their price objective on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. TD Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Truist Financial set a $158.00 target price on DaVita in a research report on Thursday, February 5th. Finally, Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $155.80.

DaVita Stock Performance

Shares of DVA stock opened at $150.94 on Friday. The company has a market capitalization of $10.08 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 0.52 and a beta of 0.94. The company has a 50-day simple moving average of $127.93 and a 200 day simple moving average of $126.65. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $159.42.

DaVita (NYSE:DVA) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.16. The firm had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business’s revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Sell-side analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.